Nuvectis Pharma reported its third‑quarter 2025 financial results, showing a net loss of $7.5 million for the quarter, compared with a $4.2 million loss in the same period of 2024.
Cash and cash equivalents increased to $35.4 million as of September 30, 2025, up from $18.5 million at the end of 2024. The increase was driven by a February 2025 public offering that raised approximately $15.5 million in gross proceeds and ongoing at‑the‑market sales.
Research and development expenses rose to $5.8 million for the quarter, up from $2.8 million in the same period last year, largely due to a $2.0 million milestone payment for NXP900 and a $0.7 million drug‑drug interaction study. General and administrative costs climbed to $2.0 million, up from $1.5 million.
The company recorded an operating loss of $6.3 million, interest income of $0.3 million, and $1.5 million in non‑cash stock‑based compensation. Net loss for the nine months ended September 30, 2025, was $19.1 million, compared with $10.3 million for the same period in 2024.
Nuvectis highlighted progress on its lead asset, NXP900. The Phase 1b program has commenced as a single‑agent study, and a combination component with EGFR and ALK inhibitors is expected to begin shortly. The company also reiterated its focus on advancing NXP900 while evaluating other indications for NXP800.
The company had no revenue in the quarter, consistent with consensus revenue estimate of $0. The consensus EPS estimate for the quarter was $-0.24, and the reported net loss aligns with that expectation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.